Astellas to sale off the Oncology line by 2015

Quote

Anonymous said:
I am attending the ESMO, it is so shameful to see our Oncology Medical Affairs folks being wasted in Madrid's resturants and bars.
I am not sure what these guys do here. I have seen them do nothing. What a waste of money. These folks that are from US office are worthless. I have seen them more being wasted than actually being in a meeting.
Why Andree is here, shouldn't be in U.S. Taking care of his mess there? What is Gabriel doing except eating and drinking? No wonder they want to sell the Oncology line. Who checked these people expense reports? They look so dysfunctional. Why do we need this many medical folks attending this meeting? Why there are US medical team attending the European meeting?
They are just creating more mess and confusion. What the heck is going on in this company? Who is in charge of Oncology. Feels like a party here in Madrid and no one interested of attending the meeting. Where is the Compliance?
They should sell the Oncology group. All useless with NO leadership. I agree with Kenji that this Medical Affairs is useless. We need some leaders or we are better without Oncology.
Click to expand...

Get over yourself. I have no idea why you are so concerned about the company selling the Oncology division. Why don't you mind your own business!
 
















It is true, activities in Oncology will slow to almost stop, no more new drug or pipeline adventure, this was confirmed indirectly by Hatanaka last week while in Northbrook.
 








just read JR's interview in PinkSheet. What a bunch of lies. There will be no expansion in Oncology. There are no teams nor any experts who are evaluating anything with any company. Frankly, no company wants to have anything with us.
When we have a PharmD running a development in Oncology, how can we truly evaluate and make decisions. By the way, there are many good PharmD's out there with the knowledge of drug development but not this one. She was a project manager at Takeda, as a result we are not even lead for any Xtandi Registration trials, never the less thinking about expansion. Ask yourself, what was the last successful drug that was developed by Astellas, NOT OSI, or Medivation.From BD perspectives, look at what happened and how much we wasted with AVEO. Even Medivation is very unhappy with our partnership.
His talk is to just boost the sales of Xtandi and nothing else. Unfortunately due to coming to market 2nd and Abiraterone going generic soon, Xtandi despite. Ding a good drug, will never catch up with market leaders.
 








You are just bitter and negative. Validate your claims (non-sense) or get off the board. What is it with people who bash one of the brightest places to work in the industry? Xtandi has a long life ahead of it and so does our opportunity to grow the division. If you don't want to be here, leave.
 








Recently hired outside Corp Communications team will provide plenty of "spin" on Astellas. Just more lipstick on a pig. All signals point to sell off or merger with another Jap company.
 
























"Recently hired outside Corp Communications team will provide plenty of "spin" on Astellas. Just more lipstick on a pig. All signals point to sell off or merger with another Jap company." This is correct.
 








Anonymous said:
"Recently hired outside Corp Communications team will provide plenty of "spin" on Astellas. Just more lipstick on a pig. All signals point to sell off or merger with another Jap company." This is correct.
Click to expand...

I could see merger or sell off of whole company but never just the oncology franchise. It's the only bright spot in the company...
 








They should sell the Oncology division. Over heard this older lady who claimed to be a head of development bragging about how much money she is making and how little work she has been doing. She was claiming, she was retiring from her last job but they brought her here and are giving her boat load of money to do nothing.

Did some research and yes, she is a Pharm.D., used to be a project director at Millenium BUT now is a SVP of Oncology development here. You figure it out. This shows we are not serious about Oncology. What a bunch of losers.
 








Anonymous said:
Despite success of Xtandi in prostate cancer market, Astellas leadership is planing to sell the rights for Tarceva, Xtandi and other marketed Oncology products to raise money for the upcoming merger in 2015.
The action is supported by lack of Oncology pipeline activities in clinical development, Tarceva upcoming loss of patent and analysts predicted massive blow to Xtandi's sale in USA as a result of Abiraterone Acetate generic market by 2016/2017.
ASTELLAS leadership in Japan has decided to concentrate more in what they believe are good at: Acting as 3rd party, marketing and selling other companies products as well Urology and Transplant and NOT being involved in more technical products such as Oncology, Immunology etc.
This maybe a very logical solution as the merging company will NOT contain any Oncology product.
Click to expand...

Exactly who are we merging with?
 








































From 3Q result Xtandi sales numbers, it does not appear that they are catching up with Zytiga, adjusting per launch year. Although good money but it makes sense to sale the Oncology compounds (in this case Xtandi) since there is not much time for Tarceva, to a buyer such as Medivation or other buyers to raise money for other franchise which may be more complimentary to Astellas (I.e.; Pain, Rare Disease etc). It is obvious that Astellas is NOT serious about Oncology.
 








the beauty of cafepharma is the anonymity of it all. This entire post is a farce. AST will not be selling off ONCOLOGY. It make absolutely NO sense. There is plenty of patent time left for Tarceva. Xtandi is doing very well. We can't just buy MDVN. It does not work that way.
 








you have read it wrong. Writer has stated that Medivation may want to buy Astellas. Now, this makes sense as Astellas has paid for most trials and benefits, if any, from those trials will be more blessing for Medivation than Astellas.

If Astellas is truly after merger etc and needs more money, it makes complete sense to raise the money one way or another.

Astellas is NOT serious about Oncology, see who is running it, clinically as well as commercially. You tell me what we have in pipeline, there is no investment. Enzalutamide will be affected when Abi goes generic, that is a reality. This is not too far. Everything about Tarceva is handled by Genentech NOT Astellas, don't kid yourself.
 








Medivation or others have capabilities to take over and do a much better job than our useless Oncology leadership. We have nothing, Xtandi is Medivation product and Tarceva is Genentch's product. There is nothing in our pipeline nor any business development activities. Our head of Oncology Development is a project manager with no Oncoligy training and our Marketing strategist is pretty blonde boy who doesn't know anything about Oncology and all he does is kisses up to Japan. We will be better working for others.
 








Top Bottom
Back
Quote